- Home
- NVNO vs TARA Comparison
NVNO vs TARA Comparison
Compare NVNO & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNO
- TARA
- Stock Information
- Founded
- NVNO 1987
- TARA N/A
- Country
- NVNO United States
- TARA United States
- Employees
- NVNO N/A
- TARA N/A
- Industry
- NVNO Medical/Dental Instruments
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVNO Health Care
- TARA Health Care
- Exchange
- NVNO Nasdaq
- TARA Nasdaq
- Market Cap
- NVNO 59.4M
- TARA 52.4M
- IPO Year
- NVNO N/A
- TARA N/A
- Fundamental
- Price
- NVNO $3.30
- TARA $2.29
- Analyst Decision
- NVNO
- TARA Strong Buy
- Analyst Count
- NVNO 0
- TARA 2
- Target Price
- NVNO N/A
- TARA $24.00
- AVG Volume (30 Days)
- NVNO 117.4K
- TARA 187.3K
- Earning Date
- NVNO 10-31-2024
- TARA 11-12-2024
- Dividend Yield
- NVNO N/A
- TARA N/A
- EPS Growth
- NVNO N/A
- TARA N/A
- EPS
- NVNO N/A
- TARA N/A
- Revenue
- NVNO N/A
- TARA N/A
- Revenue This Year
- NVNO N/A
- TARA N/A
- Revenue Next Year
- NVNO N/A
- TARA N/A
- P/E Ratio
- NVNO N/A
- TARA N/A
- Revenue Growth
- NVNO N/A
- TARA N/A
- 52 Week Low
- NVNO $3.01
- TARA $1.13
- 52 Week High
- NVNO $6.97
- TARA $5.24
- Technical
- Relative Strength Index (RSI)
- NVNO 43.55
- TARA 48.52
- Support Level
- NVNO $3.24
- TARA $2.21
- Resistance Level
- NVNO $3.75
- TARA $2.74
- Average True Range (ATR)
- NVNO 0.18
- TARA 0.16
- MACD
- NVNO 0.02
- TARA -0.05
- Stochastic Oscillator
- NVNO 12.62
- TARA 14.04
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).